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CancerAbstract In this review article, we highlight the importance of low-density lipoprotein (LDL) and
its implications in the ﬁeld of drug delivery to cancer cells. LDL is naturally occurring bionanopar-
ticles (BNP) with a size of 18–25 nm. These BNPs speciﬁcally transport cholesterol to cells express-
ing the LDL receptors (LDLRs). Several tumors overexpress LDLRs, presumably to provide
cholesterol for sustaining a high rate of membrane synthesis. LDL BNPs are biocompatible and
biodegradable, favorably bind hydrophobic and amphiphilic drugs, are taken up by a receptor-med-
iated mechanism, have a half-life of 2–4 days, and can be rerouted. Drugs can be loaded onto LDL
BNPs by surface loading, core loading, and apoprotein interaction. LDL may be used as a drug
carrier for treatment of atherosclerosis, cancer, and in photodynamic therapies.
ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Contents
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Nanoparticulate matter is a collection of particles with at least
one dimension that is smaller than 1 lm but larger than atoms
and molecules. The size of nanomaterials is similar to that of
most biological molecules and structures (Buzea et al., 2007).
Fig. 1 represents deﬁnition of nano and micro sizes and some
biological nanomaterials.
The therapeutic or diagnostic agents of interest are encap-
sulated within nanoparticles using a polymeric matrix and
are adsorbed or conjugated onto the nanoparticle surface
(Misra et al., 2010). Nanoparticles may be targeted to speciﬁc
sites via the receptors on target cells that elicit speciﬁcFigure 1 Represents size of nanomaterials compared to biolobiochemical interactions (Misra et al., 2010). The universal
structural topology of nanoparticles consists of a core com-
partment with terminal surface groups (Misra et al., 2010).
Nanosized materials (5–100 nm) are used in various applica-
tions. The use of therapeutic nanoparticles as unique drug
delivery systems will soon be a signiﬁcant addition to current
cancer therapeutics. This technology has enabled the manipu-
lation of the biological and physicochemical properties of
materials to facilitate more efﬁcient drug targeting and delivery
(Buzea et al., 2007).
Bionanotechnology, a subdivision of nanotechnology
focuses on the development of novel nanoscalematerials from
biological building blocks (Lee and Wang, 2006). Naturalgical components and deﬁnition of nano and micro sizes.
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et al., 2005), lipoproteins (Skajaa et al., 2011) and nanoery-
throsomes (Paygude, 2013). Viral nanoparticles are emptied
viruses with a diameter of 30 nm that can carry drugs. They
are naturally biocompatible, particularly with viruses that do
not cause human diseases (Singh et al., 2007). Some viruses
have a natural afﬁnity for receptors on tumor cells, such as
transferrin receptors (Singh et al., 2006).
Nanoerythrosomes have been proposed as encapsulation
systems for macromolecular drugs (Paygude, 2013). They
added beneﬁts like greater retention time, bypasses macro-
phage uptake and systemic clearance (Paygude, 2013). The
use of nanoerythrosomes looks promising for a safe and sure
delivery of various drugs (Paygude, 2013).
Nucleic acids, ferritins, self-assembled protein cages, en-
zyme complexes and peptides have been extensively studied
as starting materials for nanomaterial synthesis. These bio-
genic systems self-assemble primarily based on multiple
non-covalent interactions to become highly organized nano-
systems with a diverse array of shapes and sizes (Lee and
Wang, 2006).
Lipoproteins are BNPs that transport cholesterol and other
lipids in the blood; their size ranges from 8 to 1200 nm. Be-
cause they are endogenous carriers, lipoproteins are not recog-
nized as foreign entities by the human immune system and are
not absorbed by the reticuloendothelial system (RES). As a re-
sult, lipoprotein nanoplatforms may provide a solution to the
biocompatibility issues associated with most synthetic nano-
structures (Zheng et al., 2005).
The targeting of tumor cells by antineoplastic drugs is often
characterized by low selectivity. As a result, different types of
natural and synthetic delivery systems have been proposed as
carriers for improving the selectivity of antitumor drugs (Polo
et al., 2002; Singh et al., 2007). Nanoparticles can be targeted
to cancer cells by attaching monoclonal antibodies or cell-sur-
face receptor transporter ligands that bind speciﬁcally to mol-
ecules found on the surfaces of target cells (Zheng et al., 2005).
A number of receptors for hormones, growth factors, folic
acid, vitamin B12, low density lipoprotein receptors (LDLRs)
and others are overexpressed in cancer cells (Sega, 2008). The
overexpression of the LDLRs in various tumor cells has been
attributed to the large quantities of cholesterol and fatty acids
required for supporting rapid proliferation. Therefore, the
incorporation of drugs into low density lipoprotein (LDL)
may be an efﬁcient method of targeting tumor cells (Firestone,
1994; Lundberg, 1993). LDL is naturally occurring bionano-
particles (LDL BNPs) that has long been used as vehicles for
the selective delivery of diagnostic and therapeutic agents to
tumor cells (Zheng et al., 2005).
LDL BNPs are recognized by and internalized in cells
through speciﬁc membrane receptors that interact with the
apoprotein B-100 (apoB-100) (Polo et al., 2002). The entry
of nanoparticles into cells is mediated by several mechanisms,
including clathrin-mediated transport, caveolae-dependent
endocytosis, macropinocytotic uptake (Radu et al., 2010).
Other mechanisms such as electrostatic forces, Van der Waals
or steric interactions are involved in the entry of nanoparticles
into cells (Radu et al., 2010).
The purpose of this review article is to highlight the use of
LDL BNPs as a system of drug delivery to cancer cells and to
discuss the opportunities and challenges faced by the use of
LDL BNPs. The properties of LDL BNPs and the mannerin which these properties affect the efﬁciency and speciﬁcity
of BNPs as a drug delivery system are described. We will also
discuss the advantages and disadvantages of LDL BNPs and
the attempts to improve their therapeutic efﬁcacy in cancer
treatment.2. Lipoproteins as natural drug delivery systems
Lipoproteins are spherical nanoparticles characterized by an
insoluble core consisting of cholesteryl esters and triacylglyc-
erol surrounded by a shell of amphipathic phospholipids and
specialized proteins termed apolipoproteins (Wasan and Cassi-
dy, 1998). Lipoproteins differ in their content of proteins and
lipids and are classiﬁed into ﬁve main categories based on their
density: chylomicrons, very low-density lipoproteins (VLDLs),
intermediate density lipoproteins (IDLs), low-density lipopro-
teins (LDLs), and high-density lipoproteins (HDLs) (Wasan
and Cassidy, 1998). Lipoproteins are conventionally described
by their density, which is reﬂected by an increased protein/lipid
ratio, and are classiﬁed by their surface apolipoprotein con-
tent, which subsequently governs the ultimate fate of the par-
ticle (Chung and Wasan, 2004). Fig. 2 shows the general
structural features of lipoproteins.
Lipid transport is regulated by apolipoproteins as well as
lipoprotein receptors, lipolytic enzymes, and transfer proteins;
all of these molecules act in concert to maintain cholesterol
and triacylglycerol homeostasis (Chung and Wasan, 2004).
The hydrophobic nutrients, such as triacylglycerols and
cholesteryl esters, are delivered from the liver and intestine
to other tissues in the body for storage or catabolism and en-
ergy production by lipoproteins (Vickers and Remaley, 2013).
Many of the recently discovered functions of HDL are, in fact,
not strictly conferred by its ability to promote cholesterol ﬂux,
but by the other molecules it transports, including a diverse set
of proteins, small RNAs, hormones, carotenoids, vitamins,
and bioactive lipids (Vickers and Remaley, 2013). Based on
the ability of HDL to interact with almost all cells and trans-
port and deliver fat-soluble cargo, HDL has the remarkable
capacity to affect a wide-variety of endocrine-like systems
(Vickers and Remaley, 2013).
Lipoproteins are also involved in other biological processes,
including coagulation, tissue repair, and immune reactions
(Wasan and Cassidy, 1998). Lipoproteins also have a strong
potential to serve as drug-delivery vehicles due to their small
size, long residence time in the circulation and high-drug pay-
load (Alanazi, 2003; Sabnis and Lacko, 2012). Consequently,
lipoproteins and synthetic/reconstituted lipoprotein prepara-
tions have been evaluated with increasing interest toward clin-
ical applications, particularly for cancer diagnostics/imaging
and chemotherapy (Sabnis and Lacko, 2012).
Lipoproteins transport hydrophobic drugs, including halo-
fantrine, amphotericin B, and cyclosporine. Furthermore, lipo-
proteins are the major transporters of vitamin E in circulation
(Chung and Wasan, 2004). Also, antiarrhythmic, antidepres-
sants, antimalarials, antifungals, and immunosuppressant,
associate with plasma lipoproteins. The pharmacokinetic
properties, tissue distribution, and pharmacological actions
of these drugs are affected by their interactions with lipopro-
teins (Chung and Wasan, 2004).
Understanding the binding mechanisms of lipoproteins and
hydrophobic drugs can predict their therapeutic effects and
Figure 2 General structure of lipoproteins. Lipoproteins are particles composed of an inner core of nonpolar lipids (triacylglycerol and
cholesteryl esters) surrounded by amphipathic lipids (phospholipids and cholesterol) and proteins, making the particle water miscible. This
combination of hydrophilic and hydrophobic properties enables lipoproteins to associate with lipids and hydrophobic compounds in order
to transport in the plasma. The particle size of lipoproteins ranges from 10 to 1200 nm, and the size of each type of lipoprotein is as
follows: chylomicron, 75–1200 nm; VLDL, 30–80 nm; IDL, 25–35 nm; LDL, 18–25 nm; and HDL, 8–12 nm.
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lipoproteins loaded with therapeutic agents are taken up by
cells may provide novel methods for drug delivery and target-
ing (Chung and Wasan, 2004).
In the last few decades, LDL has been investigated for its
ability to deliver drugs to cells expressing the receptors (Gu
et al., 2011; Jiang et al., 2006). Because most tumor cells over-
express LDLRs, these receptors have been utilized as a delivery
method for a number of anticancer drugs (Glickson et al.,
2009). The role of lipoproteins in lipid transport and drug
delivery is illustrated in Fig. 3.
2.1. Lipoproteins as bionanoparticles (BNPs)
Lipoproteins are BNPs consisting of hydrophobic core (cho-
lesteryl esters and triacylglycerol), amphipathic shell (phospho-
lipids and free cholesterol) and apolipoproteins (Skajaa et al.,
2011). The particle size of lipoproteins ranges from 10 to
1200 nm, and the size of each type of lipoprotein is as follows:
chylomicron, 75–1200 nm; VLDL, 30–80 nm; IDL, 25–35 nm;
LDL, 18–25 nm; and HDL, 8–12 nm (Glickson et al., 2009).3. LDL as a bionanoparticle
LDL is a spherical BNP with a particle size of 18–25 nm and is
composed of a core and surface coat. The core is hydrophobic
and consists of esteriﬁed cholesterol and triacylglycerol (Alan-
azi et al., 2004). An LDL particle also contains an outer sur-
face layer of phospholipids surrounded by a single apoB-100
protein (Prassl and Laggner, 2009). Free cholesterol interca-
lates between the phospholipid fatty acid chains, providing adegree of rigidity to the LDL outer coat phospholipid mono-
layer (Nikanjam et al., 2007a). LDL contains approximately
50% free and esteriﬁed cholesterol, 25% proteins, 20% phos-
pholipids, and 5% triacylglycerol. Over 95% of the LDL apo-
protein is apoB-100 (Rajman et al., 1999). apoB-100 is exposed
at the surface, allowing for receptor recognition with nine ami-
no acids at residues 3359–3367 serving as the binding domain
for the LDLR (Segrest et al., 2001). Fig. 4, displays schematic
model of an LDL nano-particle.
The most important role of LDL is the delivery of choles-
terol to extrahepatic tissues for utilization in a number of pro-
cesses, including steroid production and membrane synthesis
(Fielding and Fielding, 1996).
LDL particles have multiple distinct subspecies that differ
in particle size and particle number (Berneis and Krauss,
2002). Particle number and particle size can be efﬁciently mea-
sured by nuclear magnetic resonance spectroscopy. Analytical
studies have shown that LDL particles exhibit a large hetero-
geneity of size, density, and composition due to differences
in their relative contents of cholesterol esters, triacylglycerol,
and apoB-100 (El Harchaoui et al., 2007). This heterogeneity
has been identiﬁed through the use of density gradients, rate
zonal and analytical ultracentrifugation, and non-denaturing
gradient gel electrophoresis (Krauss, 1994). Distinct LDL sub-
populations vary in isoelectric point, electrical charge, hydro-
dynamic properties, and immunoreactivity (Chapman et al.,
1988).
Measurements of LDL subfraction diameters using staining
electron microscopy have established that the mean particle
diameter decreases with increasing density. The structure of
LDL particles of different densities varies with respect to both
the size of the core and the width of the surface shell (Rajman
Figure 3 Role of lipoproteins in transport of lipids and delivery of hydrophobic drug delivery. Lipoprotein-mediated lipid and drug
transport in mammals involves several different lipoproteins. The hydrophobic nutrients, such as triacylglycerols and cholesteryl esters,
are delivered from the liver and intestine to other tissues in the body for storage or catabolism and energy production by lipoproteins. As
well the drugs can be delivered by similar mechanism.
508 G.I. Harisa, F.K. Alanaziet al., 1999). LDL subfraction patterns were divided into four
main groups: LDL I to LDL IV (Austin et al., 1988). In an
alternative classiﬁcation based on particle diameter, two major
subclasses of LDL in each proﬁle are: subclass A, with a par-
ticle diameter of 25.5 nm or greater, and subclass B, with a
particle diameter less than 25.5 nm (Austin et al., 1988). Indi-
viduals with the pattern B LDL subclass had higher triacyl-
glycerol and cholesterol compared to those with pattern A
LDL (Maki et al., 2000). In kinetic turnover studies, where
the quantity of radioactive products with labeled LDL was
measured in the urine, two LDL pools were found: a rapidly
cleared pool A, likely consisting of larger LDL particles, and
a slowly cleared pool B, likely consisting of smaller LDL par-
ticles (Rajman et al., 1999).
3.1. The LDL receptors
The LDLR is a single-chain transmembrane glycoprotein
responsible for the binding and endocytosis of LDL and isthe founding member of the LDLR superfamily (Xu et al.,
2013). Each member of the LDLR family undergoes recep-
tor-mediated endocytosis, is expressed in a number of different
tissues and has a wide range of different ligands that are not
speciﬁc to the LDL particle. The LDLR consists of ﬁve distinct
domains, including a ligand binding domain, epidermal
growth factor (EGF) precursor-homology domain, O-linked
sugar domain, membrane-spanning domain, and cytoplasmic
tail (Brown and Goldstein, 1986).
The ligand binding domain consists of 292 amino acids with
40 amino acids repeating 7 times (with little variation). This
domain has many cysteine residues, which cluster with nega-
tively charged amino acids, to form binding sites for apoB-
100. EGF precursor homology region (containing approxi-
mately 400 amino acids) is like the EGF precursor. O-linked
sugar chains bond to the 58 amino acids found in the third do-
main. The hydrophobic domain consists of 22 hydrophobic
amino acids that span the cell membrane. The cytoplasmic do-
main or the cytoplasmic tail (containing 50 amino acids) is
Figure 4 Schematic model of LDL nano-particles. Spherical
LDL BNP with a particle size of 18–25 nm and is composed of
hydrophobic core consists of esteriﬁed cholesteryl and triacylglyc-
erol. An LDL particle also contains an outer surface layer of
phospholipids surrounded by a single apoB-100 protein. Free
cholesterol intercalates between the phospholipid fatty acid chains.
Figure 5 The LDL receptor structure. The LDLRs consist of
ﬁve distinct domains, including a ligand binding domain, epider-
mal growth factor (EGF) precursor-homology domain, O-linked
sugar domain, membrane-spanning domain, and cytoplasmic tail.
Ligand binding domain has negative that allows the binding of
positive charge residue of apoB-100.
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endocytosis vesicles (Brown and Goldstein, 1986). Fig. 5 repre-
sents the structure of LDLR.
The LDL receptor transports speciﬁc macromolecules, pri-
marily the cholesterol-rich lipoprotein LDL, into cells through
a process called receptor-mediated endocytosis. The LDLR
binds to LDL and the complex is internalized through the
clathrin-dependent pathway. In this process, the cell surface
receptor recognizes an LDL particle from the extracellular
membrane (Xu et al., 2013).Uptake of LDL particles occurs through both receptor-
and non-receptor-mediated pathways. On average, 30–40%
of the total plasma pool of LDL is cleared from the body
each day, and of this portion of the circulating LDL pool,
approximately two thirds are removed by receptor-mediated
uptake (Wasan and Cassidy, 1998). Through electrostatic
interactions between the highly cationic receptor binding se-
quences on apoB-100 and the complementary anionic se-
quences on the cell surface, the LDL particle binds to the
LDLR embedded in clathrin coated pits on the cell surface
(Brown and Goldstein, 1986).
The receptor-ligand complex internalizes into vesicles and is
transformed into an endosome. Inside the endosome, the
receptors dissociate from the lipoprotein and are either metab-
olized or recycled back to the coated pits at the cell surface.
Subsequently, LDL is delivered to lysosomes where it is de-
graded (Wasan and Cassidy, 1998). The turnover time for cell
surface LDLRs is approximately 24 h (Brown and Goldstein,
1986). Cholesteryl esters are hydrolyzed to free cholesterol,
the free cholesterol, now available to the cell, can be used in
the production of membranes, re-esteriﬁed and stored, or re-
moved from the cell and excreted in the bile (Wasan and Cas-
sidy, 1998). The empty LDLR is recycled to the plasma
membrane to mediate another round of LDL binding and
internalization (Xu et al., 2013). apoB-100 is broken down into
its amino acid components.
This pathway could be useful for drug delivery, and may
then be directed toward tumors expressing LDLR. Any drugs
incorporated into the LDL particle accumulate within the tar-
geted cell, providing a very effective mechanism for drug deliv-
ery (Chu et al., 2013). Accordingly, LDL-based hydrophobic/
amphiphilic drug delivery systems (DDS) can be internalized
and degraded by regular cell metabolism, and these properties
can be used in targeted therapies for cancer (Chu et al., 2013).
Fig. 6, shows cellular uptake of LDL loaded with drug.
3.2. Role of apolipoprotein B-100 in LDLR binding
apoB-100 is located on the short arm of chromosome 2 consist-
ing of 4560 amino acids and has a molecular weight exceeding
500,000 Daltons. This apoprotein is secreted from hepatocytes
as a protein compound in VLDL particles. VLDL particles un-
dergo intravascular processing during which all other types of
apoproteins are removed such that apoB-100 remains the sole
apoprotein in LDL particles. Each LDL particle contains one
apoB-100 molecule (Veniant et al., 1999).
The complete primary structure of apoB-100 has been iden-
tiﬁed, and its secondary and tertiary structures have been pro-
posed. The LDL receptor-binding domain is present at
residues 3359–3367. This domain is formed by positively
charged residues that interact with the negatively charged re-
gions of the LDL receptor (Rall et al., 1981). The function
of apoB-100 is to maintain the integrity of LDL particles
and to control the plasma levels of LDL by binding to its
receptors (Brown and Goldstein, 1986). The apoB-100 mole-
cule is modeled as a belt that surrounds the LDL particle.
Therefore, the diameter of the LDL particle and apoB-100
has implications for the binding afﬁnity of apoB-100 to its
receptors (Miserez and Keller, 1995).
A central role in this process appears to be exerted by the
arginine residue at position 3500 of the apoB-100 protein,
Figure 6 Steps of cellular uptake and recycling of LDL loaded with drug by LDLRs. Plasma LDL can be cleared from circulation
through LDL receptor (LDLR)-mediated endocytosis. This allows for the transfer of LDL into endosomes, where the pH drops, causing
LDL to dissociate from the receptor. The receptor is then recycled to the surface of the cell, while LDL is transferred into the lysosomes
for degradation. This pathway could be useful for drug delivery, and may then be directed toward tumor cell overexpressing LDLRs.
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3147–3157 and 3359–3367 that ensure the binding of apoB-
100 to the LDL receptor (Ma¨rz et al., 1993).apoB-100 can be
puriﬁed and used to reconstitute/synthesize apoB-100 contain-
ing lipoparticles as hydrophobic/amphiphilic compound deliv-
ery vehicles. The reconstituted apoB-100 lipoparticle may be
an ideal carrier for transporting hydrophobic and amphiphilic
compounds. Consequently, synthetic nanopaticles with a small
fragment of apoB-100 or LDL-dextran mixture were devel-
oped (Chu et al., 2013).
3.3. LDL and cell growth
Lipid metabolism contributes to the transformed phenotype of
cancer cells. In particular, aberrant regulation of cholesterol
homeostasis has been associated with multiple types of cancer
(Smith and Land, 2012). Because of their diverse biological
roles, lipids contribute to several aspects of tumor growth, en-
ergy production, and redox homeostasis (Santos and Schulze,
2012). Cholesterol is an essential component of the cell mem-
brane. The primary pathway of cholesterol production is de
novo synthesis; however, another mechanism of obtaining cho-
lesterol is the cellular uptake of circulating LDL. Several pieces
of evidence have demonstrated that the LDLRs have a role in
cell growth and tumorigenesis (Notarnicola et al., 2008). An
increase in levels of cholesterol was observed in tumors relative
to that in normal tissue. Moreover, low serum cholesterol lev-
els have been associated with the presence of tumors in cancer
patients, suggesting that cholesterol may accumulate in tumor
tissue (Smith and Land, 2012).3.4. The LDLRs in cancer cells
Lipoproteins are a major mechanism by which cholesterol is
transported and delivered to at least some types of cancer cells,
and some cell types may endogenously generate cholesterol.Not surprisingly, LDL plays a role in cholesterol delivery to
some types of cancers and up-regulation of the LDL receptor
in malignancy has been reported (Damiano et al., 2013).
It has been demonstrated that LDLRs are overexpressed in
various human cancer cell lines. Glioblastoma multiforme
(GBM) is a highly aggressive tumor that accounts for approx-
imately 85% of primary brain tumors in adults. A study on se-
ven GBM cell lines showed that these cells have high LDLR
expression (Chu et al., 2013). However, studies on the distribu-
tion of LDLRs in normal rat and monkey brain tissue suggest
that normal brain tissue, particularly the gray matter of the
cortex, has relatively low LDLRs (Chu et al., 2013).
Several studies have demonstrated that the LDLRs have a
role in cell growth and tumorigenesis (Notarnicola et al.,
2008). Compared to normal cells, the LDLRs are overexpres-
sed in many malignancies, including acute myelogenous leuke-
mia (three to 100-fold compared to normal cells), adrenal
adenoma (eightfold), and colon (sixfold), pancreatic, lung,
brain, and prostate cancers (Firestone, 1994). Among the lab-
oratory models of human cancer, B16 melanomas and HepG2
hepatomas are rich in LDLRs (de Smidt et al., 1990; Rensen
et al., 1997).
Overexpression of LDLRs occurs in several cancer cell lines
due to the cell’s increased need for lipids in the synthesis of
new membranes (Graziani et al., 2002). A large body of evi-
dence has demonstrated that some types of cancer cells have
high LDL requirements due to both elevated LDLRs’ levels
on rapidly growing tumor cells and a depletion of LDL in
the blood of cancer patients (Bildstein et al., 2011). Tumor
cells generally have high cholesterol requirements because they
are rapidly dividing and because cholesterol is required for new
membrane synthesis.
The LDLRs are overexpressed in several cancer cell lines
due to the rapid growth of neoplastic cells and their corre-
sponding need for structural lipids (Bildstein et al., 2011). As
a result, LDLR activity may be higher in cancer cells than in
normal cells. In fact, increased LDLR expression has been
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cers, prostate tumors, adrenal tumors, gynecological cancers,
lung tumors, leukemias, and brain tumors (Nikanjam et al.,
2007a,b). Growth factors may be important in the regulation
of LDLR gene expression (Samadi-Baboli et al., 1993).
Using immunocytochemistry to study the localization of
the LDLRs, relatively few LDLRs were found in the neurons
and glial cells of monkey and rat brains. Additionally, LDLR
binding was evaluated using homogenates from human intra-
cranial tumors and the surrounding normal tissue and shown
to be highly variable between tumor tissue and normal brain
tissue. The boronated protoporphyrin that associates with
LDL is endocytosed into the human glioblastoma cell line
(Lenka Maletınska´ et al., 2000), suggesting that LDL may be
used as a drug delivery system for tumors expressing the
LDLRs (Rensen et al., 2001).3.5. Sources of LDL
LDL was isolated from plasma using ultracentrifugation. So-
dium bromide (1.0 mL; 1.025 g/mL) containing 0.01% (w/w)
NaN3, 0.3 mmol/L Na2EDTA, and 1 mmol/L benzamide
hydrochloride was gently added to 2 mL of plasma, and the
mixture was separated by ultracentrifugation at 400,000g (at
the bottom of tube) at 4 C for 5 h. The bottom fraction
(2.0 mL) was then transferred to another tube, and the den-
sity was increased to 1.063 using NaBr (1.151 g/mL). After
another centrifugation at 400,000g at 4 C for 5 h, the top
fraction was decanted, and the container was ﬁlled with
nitrogen and stored in the dark at 4 C until analysis. The
LDL fractions were protected from the sun and artiﬁcial
light, which can cause oxidation, and analyzed within 24 h
of preparation (Aoki et al., 2012; Kader and Pater, 2002).
LDL can also be purchased from commercial suppliers (Hun-
tosova et al., 2012).
3.6. Advantages of LDL BNPs as drug carriers
Using LDL as a drug carrier may circumvent many of the is-
sues encountered with synthetic carriers, and LDL also has
important advantages compared to other nano-delivery sys-
tems (Huntosova et al., 2012). The following list provides the
characteristics of LDL particles that may be exploited if the
particle is used as a drug vehicle.
(1) LDL BNPs are natural carriers and are therefore bio-
compatible. LDL particles are non-immunogenic
because LDL escapes recognition by the mononuclear
phagocytic system. This feature may provide a solution
to the biocompatibility problem associated with most
synthetic nanodevices.
(2) LDL BNPs are biodegradable. LDL particles are inter-
nalized into cells and digested in lysosomes by acid
hydrolysis and enzymatic degradation, releasing free
cholesterol, fatty acids, and amino acids. All degrada-
tion products are recycled by the cell.
(3) The small LDL particle size of 18–25 nm is within the
ideal range of 10–100 nm for nanoparticle drug carriers.
Therefore, they are neither quickly eliminated by the
kidney nor captured by RES (Davis et al., 2008).(4) Hydrophobic drugs can be loaded in the hydrophobic
core while amphiphilic drugs can be loaded in the
amphipathic shell of LDL.
(5) Drugs are protected from hydrolytic and enzymatic deg-
radation in the plasma when sequestered in the hydro-
phobic core of LDL nanoparticles.
(6) LDL has a large core capacity. Therefore, the lipid frac-
tion can have substantial quantities of lipophilic drugs
loaded inside it. apoB-100 can also be covalently conju-
gated with a ligand or with diagnostic and therapeutic
agents.
(7) LDL BNPs may prolong the circulation half-life (2–
4 days) of drugs because they are not cleared by the
RES. Substantially unmodiﬁed LDL is also not rapidly
cleared from the bloodstream by the RES.
(8) LDL BNPs can be targeted to tumor cells because the
LDLR is highly expressed in most tumor cells. Cancer
cells require large amounts of cholesterol for the synthe-
sis of new membranes. Consequently, many cancer cells
have higher LDLRs than normal cell. Neoplastic cells
readily internalize and degrade LDL using the high-
afﬁnity receptor pathway.
(9) LDL nanoparticles may be rerouted to receptors other
than the LDLR. Alkylation of the lysine side chains of
apoB-100 eliminates LDLRs-binding activity. Alkyl-
ation of 20% of the lysine side chains completely abol-
ishes LDLR binding. Therefore, LDL nanoparticles
can be redirected to alternative targets. The alkylated
lysine e-amino side chains have appropriate receptor-
targeting ligands. The addition of folic acid ligands to
the amino groups redirects the particle to folate recep-
tors (Glickson et al., 2009).3.7. Disadvantages of LDL BNPs as a drug carrier
LDL particles are isolated from human blood, and as a result,
there is concern about the introduction of pathogens that pro-
duce infectious diseases. Commercial sources of LDL that pro-
vide pathogen-free blood proteins are available. Although
LDL has proven to be a useful vehicle for delivery of lipophilic
drugs and diagnostic agents to tumors, its application is largely
limited to LDLRs-related diseases. Speciﬁcally, it has a limited
use in cancer therapy because many tumors do not overexpress
the LDLRs, whereas some normal tissues express. Native
LDL, though, is less than ideal as a targeting agent since it
is difﬁcult to isolate in large quantities and is variable in com-
position and size (Nikanjam et al., 2007b).
A key limitation to this application is the existence of recep-
tors on normal cells, such as those in the RES that lead to high
background binding. This issue can be resolved to some extent
by judiciously selecting the targeting particle dimensions, by
attaching polyethylene glycol groups to the particle surface
to minimize non-speciﬁc binding, or by choosing appropriate
receptors, but the problem cannot yet be entirely eliminated
and remains a confounding issue in the use of this delivery sys-
tem (Glickson et al., 2009).
3.8. Methods of loading drugs into LDL particles
The hydrophobic lipid core (cholesterol esters and
triacylglycerol) and amphipathic phospholipid shell of LDL
Figure 7 Methods of loading drugs into LDL nanoparticles. The lipid and phospholipid fractions of LDL nanoparticles allow
substantial quantities of lipophilic drugs and amphipathic drugs to be loaded inside the LDL particles. The amino acid residues of apoB-
100 can be covalently conjugated with ligands or diagnostic and therapeutic agents.
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and amphipathic drugs to be loaded inside the LDL particle.
The amino acid residues of apoB-100 can be covalently conju-
gated with diagnostic ligands or therapeutic agents. There are
three ways to incorporate diagnostic and therapeutic agents
into LDL particles: protein loading, core loading, and surface
loading (Zheng et al., 2005). Fig. 7 represents the methods of
loading drugs into LDL particles.
3.8.1. Surface loading
In this method, the therapeutic agent is non-covalently bound
to the surface of the phospholipid shell. The probe is typically
conjugated to one or two long hydrophobic fatty acid chains
and to a cholesterol group. Very high product yields have been
achieved with ﬂuorescent or paramagnetic probes (Glickson
et al., 2009). Surface loading is used for either diagnostic or
therapeutic agents (Li et al., 2004) and paramagnetic Gd-che-
lated MRI probes (Corbin et al., 2006). The method is easy to
implement but prone to high leakage rates because transfer of
the surface probe to the outer phospholipid layer of the cellu-
lar plasma membrane is thermodynamically favorable. Thus,
delivery of substantial amounts of probe to cells may occur
by pathways not involved in receptor delivery (Glickson
et al., 2009).
3.8.2. Core loading
In this method, either diagnostic or therapeutic agents are
reconstituted into the non-polar cholesterol ester core of
LDL nanoparticles. Core binding was used for the agents for
photodynamic therapy (PDT) (Zheng et al., 2005). The lipid
core of LDL can be extracted with a nonpolar solvent, such
as heptane, while keeping the phospholipid and protein ‘‘shell’’
intact. As a result, the particle spontaneously reassembles with
recovery of over 50% of the LDLR binding activity. Anti-can-
cer drugs have been either directly loaded onto LDL or thecore lipids of LDL were replaced with drugs (Nikanjam
et al., 2007b). LDL contains about 1500 molecules of choles-
terol esters per LDL particle. Therefore, the development of
anticancer cholesterol conjugate compounds mimicking the
native cholesterol esters can be loaded into LDL by core load-
ing (Radwan and Alanazi, 2013). This presents a potentially
effective approach for targeted drug delivery to cancer cells
via the elevated LDL receptors (Alanazi et al.,2003).
3.8.3. Apoprotein loading
Protein loading was performed by covalent conjugation of
diagnostic or therapeutic agents to apoB-100. A number of
investigators have attached chelating groups to lysine side
chains (Glickson et al., 2009). Modiﬁcation of apoB-100 in
LDL particles results in their uptake by liver sinusoidal endo-
thelial cells. Furthermore, attachment of 18F-containing li-
gands to the lysine-e-amino groups has also been utilized for
imaging (Pietzsch et al., 2004). Radio-iodination of tyrosine
side chains for SPECT detection has been attempted but leads
to a change in the protein’s transport properties (Sobal et al.,
2004). Protein labeling has the advantage of producing stable
products; however, a disadvantage is that covalent binding
may modify the delivery characteristics of LDL because the
receptor-binding site includes reactive lysines (Glickson
et al., 2009).
4. LDL as a drug carrier
4.1. LDL as a drug carrier for atherosclerosis treatment
An excess of oxidized LDL in the aortic vasculature leads to
LDL being consumed by macrophages, transforming them into
foam cells (Ross, 1993). Over time, additional macrophages are
attracted, the vasculature becomes congested, and the excess
cholesterol forms plaques. Oxidized LDL may bind these
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able accumulation of the lipoprotein (Wang et al., 2001). This
spontaneous accumulation of LDL at a target site makes
LDL an ideal carrier for a therapeutic drug (Alanazi, 2003;
Tauchi et al., 2000). In fact, dexamethasone, which prevents
macrophage transformation into foam cells, was loaded into
human LDL as palmitoyl dexamethasone, and after intrave-
nous injection, the level of dexamethasone-loaded LDL was in-
creased in the aorta and persisted for 7 days (Tauchi et al.,
2001).
4.2. LDL as a drug carrier for anticancer drugs
A variety of in vitro and in vivo studies have indicated that tu-
mor cells from the colon, kidney, lung, and brain are charac-
terized by an enhanced expression of LDLRs. In many cases,
the incorporation of drugs into the large LDL lipid vesicle
does not impair their recognition by the LDLRs. Indeed, death
of cultured tumor cells has been induced using various drug–
LDL complexes (Polo et al., 2002). Lipoproteins may also be
used as endogenous carriers to target tumor cells, which have
high lipoprotein receptor activities (Jiang et al., 2006).
LDL may be used as carriers to conjugate water-insoluble
anti-cancer drugs to lead to a higher accumulation of the drugs
at speciﬁc locations (Jiang et al., 2006). This property may al-
low the particle to deliver its loaded drugs and avoid drug deg-
radation (Lou et al., 2005). LDL has a high afﬁnity for, and
may accumulate in, tumor cells. LDL has also been used as
a carrier to deliver anti-tumor drugs into hepatoma cells to
treat hepatocellular carcinoma (Jiang et al., 2006).
Masquelier et al. (2000) investigated the possibility of using
LDL as a drug carrier to increase the selectivity of anti-tumor
drugs in cancer chemotherapy and found that the sequestering
of anti-tumor agents with LDL does not inﬂuence the charac-
teristics of the drugs (Jiang et al., 2006). Doxorubicin (DOX)
has been coupled to human LDL to form an LDL-DOX com-
plex. When the complex was injected into mice, more LDL-
DOX accumulated in the liver than free DOX. In contrast, less
LDL-DOX accumulated in the heart than free DOX (Chu
et al., 2001). The synthetic lipoprotein coined ‘‘nano-LDL’’
targets cancer cells, speciﬁcally glioblastoma multiforme, is
composed of a peptide fragment anchored to the particle via
a lipid and binds the LDLRs (Nikanjam et al., 2007b). The
nano-LDL particle was able to incorporate the paclitaxel pro-
drug at 0.33 mg/mL; the resulting nanoparticle was highly
toxic to multiple glioblastoma multiforme cell lines expressing
variable amounts of the LDLRs (Hackett et al., 2013). Most
neurons do not express high levels of the LDLRs, which
may make this vehicle highly selective for glioblastoma multi-
forme cells in the brain (Hackett et al., 2013).
4.3. LDL as a drug carrier for anticancer photodynamic therapy
Photodynamic therapy (PDT), the systemic administration of
photosensitizers (PTS) followed by a local photoactivation of
PTS, is a promising method for the treatment of solid tumors
(Wilson and Patterson, 2008). Some porphyrins and other red
light-absorbing photosensitizing agents, such as chlorins and
phthalocyanines, accumulate in large amounts and areretained for prolonged periods of time by a variety of malig-
nant lesions (Polo et al., 2002). Once photoactivated by irradi-
ation with selected light wavelengths, the tumor-localized
photosensitizers generate highly cytotoxic reactive oxygen spe-
cies, inducing irreversible damage in the neoplastic tissue (Polo
et al., 2002). PDT is currently approved for the treatment of
bladder, esophageal, and lung tumors for both curative and
palliative purposes. Several lines of evidence indicate that the
efﬁciency and selectivity of tumor targeting by porphyrins
and their analogs are enhanced by increasing the hydrophobic-
ity of the molecule (Polo et al., 2002).
Suitable formulations of PDT agents in liposomal vesicles
or LDL particles have been developed to allow for the systemic
administration of poorly water-soluble porphyrin derivatives.
Pharmacokinetic studies with tumor-bearing mice demon-
strated that various liposome-associated porphyrinoids are
efﬁciently transferred to serum lipoproteins, particularly to
LDL, upon intravenous injection and consequently lead to a
high tumor uptake (Polo et al., 2002). However, many PTS
used in PDT are hydrophobic or amphiphilic and cannot sim-
ply be injected intravenously. In general, moderately hydro-
phobic PTS are preferentially transported in the bloodstream
by albumins, whereas highly hydrophobic PTS interact mainly
with lipoproteins, especially with LDL (Sharman et al., 2004).
As a result, LDLmay play a key role in the targeted delivery
of hydrophobic and amphiphilic PTS to tumor cells in PDT (Jin
et al., 2011). The targeted delivery of drugs in complex with
LDL into tumor cells is possible due to the enhanced expression
of speciﬁc LDLRs in many types of transformed cancer cells
compared to non-transformed cells (Huntosova et al., 2012).
5. Conclusions
LDL is a BNP that speciﬁcally transports cholesterol to cells
expressing LDLRs. Because the LDLRs exhibit binding spec-
iﬁcity, they can target drugs to site-speciﬁc cells. The properties
of LDLs, such as small size, amphiphilic surface chemistry,
and receptor-mediated uptake make them ideal candidates
for therapeutics, imaging agents, and drug delivery vehicles.
The size distribution of these LDLs ﬁrmly within the nano-
scale, advances within nanotechnology will continue to enable
the development of these biomimics and to expand their poten-
tial into the therapeutic realm. LDL-BNPs can be directed spe-
ciﬁcally to tumor cells. As drug delivery system LDLs are
biocompatible and biodegradable, have a longer half-life,
and can be rerouted. Drugs can be loaded into LDL BNPs
by surface loading, core loading, and apoprotein interactions.
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